Plus Therapeutics, Inc. (PSTV)
| Previous close | 1.8400 |
| Open | 1.8000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.8000 - 1.8000 |
| 52-week range | 0.9700 - 5.0900 |
| Volume | |
| Avg. volume | 30,533 |
| Market cap | 7.838M |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Benzinga
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs. The award is expected to commence in Q3 2024 and will support the planned expansion of the company's clinical trial for pediatric brain cancer. "This recent award further extends our current cash runway in the second half of 2025 while supporting the 2024 expansion of our clinical development activities
- Insider Monkey
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript March 5, 2024 Plus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.7, expectations were $-0.78. PSTV isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen. Welcome […]
- Simply Wall St.
Plus Therapeutics Full Year 2023 Earnings: Beats Expectations
Plus Therapeutics ( NASDAQ:PSTV ) Full Year 2023 Results Key Financial Results Revenue: US$4.91m (up by US$4.69m from...
